The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

The company is paying $350 million upfront, and potentially $1.2 billion overall, for a radiopharmaceutical for prostate ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...

The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity ...

The offer is the latest in a series of deals by Concentra, an entity controlled by Tang Capital Partners, to buy struggling ...

A "sub-study" of a large clinical trial found the drug, obicetrapib, significantly reduced levels of a type of tau protein ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

It’s a truth that all clinical teams are aware of: risk mitigation is a core part of clinical trial success. But, what does ...

Sometimes, the right advances in medicine catch the public’s imagination—opening a world of possibilities that inspires ...